LETI-101 has demonstrated therapeutically relevant reductions of mutant huntingtin (HTT) protein, exceeding 80%, while preserving essential ...

ElevateBio is seeking out partnerships for its lead gene therapy after the construct reduced the levels of a toxic protein in ...

The two companies claim AGN-151587 (EDIT-101) for Leber congenital amaurosis type 10 (LCA10) – an inherited form of blindness – is the first ‘in vivo’ CRISPR medicine to be administered to ...

CRISPR Therapeutics AG (NASDAQ ... Beam Therapeutics' BEAM-101 and Tessera Therapeutics' in vivo editing programs, while not immediate threats, represent potential future competition.

The BRILLIANCE study of EDIT-101 in Leber congenital amaurosis type 10 (LCA10) – an inherited form of blindness – was reported to be the first 'in vivo' CRISPR/Cas9 medicine to be administered ...

Verve Therapeutics remains a high-reward investment despite setbacks. Click here to find out why VERV stock is a Buy.

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Sarepta Therapeutics (SRPT – Research Report), Arcus ...

CRISPR Therapeutics CRSP stock rose more than 25% in the past week, thanks to the encouraging fourth-quarter 2024 results and ...

Allogene Therapeutics is developing allogeneic CAR-T cells for cancer and autoimmune diseases. Read why I'm bullish on ALLO ...

Editas Medicine, Inc.’s EDIT share price has surged by 83.91%, which has investors questioning if this is right time to sell.

Shares of Editas Medicine, Inc. (NASDAQ:EDIT – Get Free Report) have received a consensus rating of “Hold” from the fourteen brokerages that are currently covering the firm, MarketBeat reports. Two ...

Its 3-year beta, a measure of volatility relative to the broader market, is 1.8. Related: Cathie Wood buys $37 million of ...